The role of negative symptoms and cognitive dysfunction in schizophrenia outcome

International Clinical Psychopharmacology

Volumn 13, Issue SUPPL. 3, 1998, Pages

  Tamminga, Carol A ^a   Buchanan, Robert W ^a   Gold, James M ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Cognitive impairment; Negative symptoms; Schizophrenia

Indexed keywords

COGNITIVE DEFECT; DEPRESSION; DISEASE SEVERITY; HUMAN; INTELLIGENCE QUOTIENT; NEGATIVE SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0031776804     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199803003-00004     Document Type: Review

References (45)

1. Addington J, Addington D (1992). Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia. J Psychiatry Neurosci 18:18-23.
2. Arnt J, Skarsfeldt T, Hyttel J (1997). Differentiation of classical and novel antipsychotics using animal models. Int Clin Psychopharmacol 12 (suppl 1):S9-S17.
3. Arvanitis LA, Miller BG (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42:233-246.
4. Beasley CM, Tollefson GD, Tran P, Satterlee W, Sanger T, Hamilton S (1996). Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
5. Blanchard J, Neale J (1994). The neuropsychological signature of schizophrenia: generalized or differential deficit? Am J Psychiatry 151:40-48.
6. Buchanan RW, Gold JM (1996). Negative symptoms: diagnosis, treatment and prognosis. Im Clin Psychopharmacol 11:3-11.
7. Buchanan RW, Holstein C, Breier A (1994). The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Soc Biol Psychiatry 36:717-725.
8. Cannon T, Zorrila L, Shtasel D, Gur RE, Marco EJ, Mobery P, Price RA (1994). Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry 51:651-661.
9. Carpenter WT Jr, Buchanan RW (1994). Schizophrenia. N Engl J Med 330:681-690.
10. Cassens G, Inglis A, Appelbaum P, Gutheil T (1990). Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 16:477-499.
11. Comblatt BA, Keilp JG (1994). Impaired attention, genetics and the pathophysiology of schizophrenia. Schizophr Bull 20:31-46 [erratum in Schizophr Bull 1994, 20:248].
12. Davis JM (1969). Review of antipsychotic drug literature. In: Diagnosis and drug treatment of psychiatric disorders. Davis JM, Klein DF (editors). Baltimore: The Williams and Wilkins Company. pp. 52-138.
13. Faraone SV, Seidman LJ, Kremen WS, Pepple JR, Lyons MJ, Tsuang MT (1995). Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a diagnostic efficacy analysis. J Abnorm Psychol 104:286-304.
14. Gold JM, Goldberg TE, Kleinman JE, Weinberger DR (1991). The effects of symptomatic state and pharmacological treatment on the neuropsychological test performance of patients with schizophrenia and affective disorders. In: Handbook of clinical trials: the neurobehavioral approach. Brouwers P, Mohr E (editors). Amsterdam: Swets and Zeitlinger. pp. 185-216.
15. Goldberg SC, Gold JM (1995). Neurocognitive functioning in patients with schizophrenia: an overview. In: Psychopharmacology: a fourth generation of progress. Bloom F, Kupfer D (editors). New York: Raven Press. pp. 1245-1257.
16. Goldberg TE, Weinberger DR (1995). Thought disorder, working memory and attention: interrelationships and the effects of neuroleptic medications. Int Clin Psychopharmacol 10:99-104.
17. Goldberg TE, Ragland JD, Torrey EF, Gold JM, Bigelow LB, Weinberger DR (1990). Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 47:1066-1072.
18. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, et al. (1993). The impact of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43-48.
19. Goldman RS, Axelrod BN, Tandon R, Ribeiro SCM, Craig K, Berent S (1993). Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. Psychopathology 26:122-126.
20. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330.
21. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, et al. (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799-804.
22. Hagger C, Buckley P, Kenny J, Friedman L, Ubogy D, Meltzer H (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702-712.
23. Hoff A, Riordan H, O'Donnell D, Morris L, Delisi L (1992). Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 149:898-903.
24. 2 long receptors expressed in Ltk-cells. Eur J Pharmacol 269:149-155.
25. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L (1976). Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet ii:924-926.
26. Johnstone EC, MacMillan JF, Frith CD, Benn DK, Crow TJ (1990). Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry 157: 182-189.
27. Johnstone EC, Frith CD, Lang FH, Owens DGC (1995). Determinants of the extremes of outcome in schizophrenia. Br J Psychiatry 167:604-609.
28. Jones P, Rogers B, Murray R, Marmot M (1995). Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 344:1398-1402.
29. Kolakowska T, Williams AO, Jambor K, Ardem M ( 1985). Schizophrenia with good and poor outcome. III: Neurological 'soft' signs, cognitive impairment and their clinical significance. Br J Psychiatry 146:348-357.
30. Kraeplin E (1919). Dementia praecox and paraphrenia. Bankley RB (translator and editor). Edinburgh: ES Livingston.
31. Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV (1994). Neuropsychological risk indicators for schizophrenia: a review of family studies. Schizophr Bull 20:103-119.
32. Meltzer HY, Thompson PA, Lee MA, Ranjan R (1996). Neuropsychological deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 14 (suppl):27-33.
33. Perlick D, Mattis S, Stastny P, Teresi J (1992). Neuropsychological discriminators of long-term inpatient or outpatient status in chronic schizophrenia. J Neuropsychiatry Clin Neurosci 4:428-434.
34. Royall DR, Mahurin RK, True JE, Anderson B, Brock IP 3rd, Freeburger I, Miller A (1993). Executive impairment among the functionally dependent: comparisons between schizophrenic and elderly subjects. Am J Psychiatry 150:1813-1819.
35. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC (1994). Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Arch Gen Psychiatry 51:124-131.
36. Skarsfeldt T (1996). Differential effect of antipsychotics on place navigation of rats in the Morris water maze. Psychopharmacology 124:126-133.
37. Silverstein ML, Fogg L, Harrow M (1991). Prognostic significance of cerebral status: dimensions of clinical outcome. J Nerv Ment Dis 179:534-539.
38. Suddath RL, Casanova MF, Goldberg TE, Daniel DG, Kelsoe JR Jr, Weinberger DR (1989). Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. Am J Psychiatry 146:464-472.
39. Sweeney J, Haas G, Shuhua L (1992). Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia. Schizophr Bull 18:283-293.
40. Tamminga CA (1997). Neuropsychiatric aspects of schizophrenia. In: American psychiatric press textbook of neuropsychiatry. 3rd ed. Hales RE, Yudofsky SC (editors). Washington (DC): American Psychiatric Press. pp. 855-882.
41. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT (1992). Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49:522-530.
42. Walker E, Savioe T, Davies D (1994). Neuromotor precursors of schizophrenia. Schizophr Bull 20:441-451.
43. Weinberger DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatiy 44:660-669.
44. Wykes T, Sturt E, Katz R (1990). The prediction of rehabilitative success after three years: the use of social, symptom and cognitive variables. Br J Psychiatry 157:865-870.
45. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154:782-791.